Electronic Prescription Monitoring Programs: A Data-Reporting Tool Designed to Prevent Drug Diversion
Release Date: October 01, 2007
Expiration Date: October 01, 2010
As digital technologies continue to advance, real-time reporting of controlled substance prescribing and use is not only possible, it is currently available. Data mining, through use of electronic prescription monitoring programs (ePMPs), is a valuable option for prescribers who want to contain risk of abuse, misuse and diversion of controlled drugs, but only when the reports are interpreted by someone who views the information as a piece of a larger picture. ePMPs are not a panacea and do not replace the current best practice approach of opioid prescribing: Universal Precautions in Pain. As an adjunct to care, with system use and report results interpretation tailored to the individual patient, ePMPs can help support patient management decisions and provide additional documentation. Controversy exists among health care providers, patients, government and law enforcement agencies on exactly how and when the information gleaned from ePMPs should be used and by whom. Until more evidence becomes available, ePMPs must be considered for use on an individual case-by-case basis and their results interpreted in relationship to all other known factors.
This activity is designed for physicians, pharmacists, physician assistants, and nurses who have an interest in enhancing their knowledge and understanding of pain management.
Upon completion of this activity, participants should be able to:
- Describe the role ePMPs play in the risk containment model relative to opioid prescribing.
- Identify who initiates and sets standards for ePMPs.
- Describe how ePMPs work and the value of the reported data to patient management.
- Cite two examples of patient-types whose care may benefit from ordering and interpreting ePMP results.
This activity is eligible for credit through October 1, 2010. After this date, this activity will expire and no further credit will be awarded.
There are no fees for participating in this activity. All participants must complete the Activity Evaluation Form. Participants must receive a minimum score of 70% on the self-assessment portion of the form to qualify for CPE credit. Certificates may be printed immediately after completing the online self-assessment and evaluation.
David Brushwood is a professor of pharmacy health care administration at the University of Florida,
College of Pharmacy. A graduate of both the school of pharmacy and the school of law at the University
of Kansas, Professor Brushwood practiced both
professions prior to joining the faculty at the Philadelphia
College of Pharmacy. Professor Brushwood spent five years at West Virginia University, and became a faculty member at the University of Florida in 1990. In 2006, he established an online part-time masters program in Pharmacy Regulation and Policy.
Professor Brushwood's research interests are in the areas of regulating for outcomes, medication error prevention, and pain management policy. He has received grant funding from numerous agencies and was twice selected as a Mayday Scholar in Pain Policy by the American Society of Law, Medicine & Ethics. Professor Brushwood recently completed an educational video documentary called "Collateral Damage in America's War on Drugs: The Battle of Redding California." His current research investigates the perspective taken by media on pain management and drug diversion.
Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of MediCom Worldwide, Inc. and Medical Learning Solutions. MediCom Worldwide, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement:MediCom Worldwide, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour(s) of Continuing Education Credit. Universal Activity Number: 827-999-07-102-H01-P
Accreditation Statement: This activity has been planned and implemented through the joint sponsorship of MediCom Worldwide, Inc. and Medical Learning Solutions. MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 07-202-197
It is the policy of MediCom Worldwide, Inc. to plan and implement educational activities in accordance with the ACCME, ACPE and California Board of Nursing. As a provider, it is the policy of MediCom Worldwide, Inc. to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities.
All program planners, faculty, and providers are required to disclose any relevant financial relationships they may have or have had within the last 12 months with the commercial supporter or the manufacturer(s) of any commercial device(s) discussed in this educational activity.
Faculty Financial Disclosure
The presenting faculty reported the following: David Brushwood has disclosed that he has no significant relationships with the grantor, Cephalon, Inc., or any other commercial company whose products and services may be related to his presentation.
Planner and Provider Financial Disclosure
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, executive director and Alan Vogenberg, RPh, FASCP, clinical advisor have nothing to disclose.
Jeffrey Gudin, MD was the clinical reviewer for this activity and has nothing to disclose. Ruth Widmer, medical writer of Corona Productions has nothing to disclose.
Conflict of Interest Resolution
To identify and resolve conflicts of interest the educational content was fully peer reviewed by a member of the MediCom Worldwide, Inc. Clinical Content Review Committee who has nothing to disclose. The resulting activity was found to provide educational content that is current, evidence based, and commercially balanced.
In accordance with MediCom Worldwide, Inc. policy, the audience is advised of the following disclosures regarding unlabeled or unapproved uses of drugs or devices: Professor Brushwood indicated that his presentation would not include the discussion of unlabeled uses of commercial products or investigational products not yet approved by the FDA for any use in the United States.
MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft®Silverlight™.
©2007 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067.
This activity is supported by an independent educational grant from Cephalon, Inc.